← FDA DRUG APPROVALS

FDA ANDA · ANDA065049

CLINDACIN ETZ

clindamycin phosphate

Sponsor: PADAGIS US

APPLICATION
ANDA065049
TYPE
ANDA
ORIGINAL APPROVAL
2000-05-25
LATEST ACTION
2020-04-03
ROUTE
TOPICAL
DOSAGE FORM
SWAB
MARKETING STATUS
Prescription

Products

CLINDAMYCIN PHOSPHATEPrescription
CLINDAMYCIN PHOSPHATE EQ 1% BASE · SWAB · TOPICAL

Approval history

2020-04-03Labeling · Supplement 16 · standardAP
2020-04-03Labeling · Supplement 23 · standardAP
2015-07-15Labeling · Supplement 13 · standardAP
2014-01-14Labeling · Supplement 11AP
2010-10-19Labeling · Supplement 10AP
2009-11-30Labeling · Supplement 9AP
2002-06-27Labeling · Supplement 5AP
2002-06-27Manufacturing (CMC) · Supplement 4AP
2001-11-21Labeling · Supplement 3AP
2001-11-21Manufacturing (CMC) · Supplement 1AP
2001-11-21Manufacturing (CMC) · Supplement 2AP
2000-05-25OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →